First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.
Stephen J KerrMark P JoyFatemeh TorabiStuart BedstonAshley AkbariUtkarsh AgrawalJillian BeggsDeclan T BradleyAntony ChuterAnnemarie B DochertyDavid Vincent FordFrederick David Richard HobbsVittal Srinivasa KatikireddiEmily LowthianSimon de LusignanRonan A LyonsJames MarpleColin McCowanDylan McGaghJim McMenaminEmily MooreJosephine-L K MurrayRhiannon K OwenJiafeng PanLewis D RitchieSyed Ahmar ShahTing ShiSarah Jane StockRuby S M TsangEleftheria VasileiouMark E J WoolhouseColin R SimpsonChris RobertsonAziz SheikhPublished in: PLoS medicine (2022)
In this study, we observed a small elevated risk of CVST events following vaccination with ChAdOx1, but not BNT162b2. Our analysis pooled information from large datasets from England, Scotland, and Wales. This evidence may be useful in risk-benefit analyses of vaccine policies and in providing quantification of risks associated with vaccination to the general public.